WALTHAM, Mass. , Sept. 10, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp . (the “Company”) (Nasdaq: OPRX), the leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced an expansion of a strategic
The availability of Micro-Neighborhood ® Targeting on the Company’s Dynamic Audience Activation Platform meets the demand of life sciences marketers by synchronizing consumer and physician marketing OptimizeRx presents panel session at Digital Pharma East: Unlocking Opportunity through HCP+DTC
– Q2 revenue of $18.8 million , increasing 36% year-over-year – Q2 gross profit increased 50% year-over-year to $11 .7 million with a gross margin of 62% – Won 8 DAAP deals during Q2 WALTHAM, Mass. , Aug. 08, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp.
WALTHAM, Mass. , July 25, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp . (the “Company”) (Nasdaq: OPRX), the leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professional (HCPs) and patients, will hold a conference call on Thursday, August
OptimizeRx Micro Neighborhood® Targeting enables pharmaceutical brands to maintain and expand campaign scale nationwide WALTHAM, Mass. , July 23, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp . (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences
The Company’s AI-guided predictive targeting platform delivered three times the return in half the time of the traditional trigger-based program WALTHAM, Mass. , July 15, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp . (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions
• 84% of Patients Arrive at Doctor Visits Underinformed • Underscores Growing Importance of HCP and DTC Alignment in Pharma Commercialization and Marketing Strategies • OPRX Closes First Combined HCP and DTC DAAP Marketing Program for Top 5 Pharma Client WALTHAM, Mass.
Q1 revenue of $19.7 million , increasing 51% year-over-year Q1 gross profit increased 64% year-over-year to $12 .2 million with a gross margin of 62% Won 9 DAAP deals during Q1 WALTHAM, Mass. , May 14, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), the leading provider of
WALTHAM, Mass. , May 06, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp . (the “Company”) (Nasdaq: OPRX), the leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professional (HCPs) and patients, today announced that management will participate
1Q24 revenue expected to grow over 40% year-over-year and come in between $18.5 - $19.2 million First quarter revenue and adjusted EBITDA to come in ahead of consensus DAAP adoption and cross selling activities are tracking ahead of internal expectations WALTHAM, Mass.